Comparing the current results to its competitors, Forte Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.14 %, recorded in the same quarter.
Forte Biosciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 39.28 %
Forte Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by intense competition and rapid technological advancement. Key competitive factors include efficacy, safety profile, method of administration, cost, promotional activities, and intellectual property protection. The company competes with commercial pharmaceutical and biotechnology firms, academic institutions, government agencies, and private and public research organizations. Many competitors possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies may also present competition, particularly through collaborations with larger entities. The company's commercial prospects may be impacted if competitors develop products that are safer, more effective, or less expensive. The company holds one U.S. patent related to the treatment of skin conditions, which is not material to its FB102 program, and has several pending international patent applications.
August 15, 2024
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company headquartered in Dallas, has announced significant developments in its operations during the second quarter of 2024, along with comprehensive financial results for the period. Since its inception, Forte has focused its efforts on addressing the unmet medical needs presented by autoimmune and autoimmune-related diseases, and the latest updates signal promising advancements in their research and development pipeline.Among the highlights of the second quarter was the successful completion of the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) phases of the FB102 study, Forte s leading therapeutic candidate targeting CD122. This mo...
Astria Therapeutics Inc's business model centers around developing and commercializing innovative therapeutics for various diseases and medical conditions.
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
Sources:
Forte Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Forte Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
